Colorado Clinical and Translational Sciences Institute
  • The National Institutes of Health (NIH) has invested nearly $470 million to build a national study population of diverse research volunteers and support large-scale studies on the long-term effects of COVID-19. The Colorado Clinical and Translational Sciences Institute (CCTSI) is playing a major role in the initiative called REsearching COVID to Enhance Recovery or RECOVER. Many of us know someone

  • image of a board game with medical imagery
    University Of Colorado Denver
    Nov 4, 2021 | 12:00 PM - 03:00 pm MT The theme of this year's HYBRID conference is COVID-19 Research in the News: What Ethical Issues Does This Raise? KEYNOTE PRESENTER: Timothy Caulfield, Research Director of the Health Law Institute at the University of Alberta. FLASH TALKS: Michelle Barron, MD COVID-19 Hindsite is 2020: Masks & Personal Stories Senior Director of Infection Prevention and
  • Findings from a new study published in the New England Journal of Medicine underscore the importance of early, intensive treatment for youth-onset type 2 diabetes. Phil Zeitler, MD, PhD, has been treating youth with type 2 diabetes for more than 20 years. He and a team of researchers published a paper today on the TODAY2 study in the New England Journal of Medicine on the long-term complications

  • The CCTSI responded to the pandemic by issuing a rapid-release RFA to address COVID-19. CCTSI leaders called it the COVID-19-Rapid Research Pilot Program. They released the RFA on Monday evening, March 30 and closed the application process just four days later. This new pilot grant program supported the development of novel diagnostic and treatment methods and innovative technologies related to

  • Adit Ginde, MD, and the Colorado Clinical Translational Sciences Institute team are spreading the word about monoclonal antibody treatment for COVID-19. As the COVID-19 pandemic continues to lurk in many communities, aided by vaccine hesitancy and the emergence of disease mutations like the Delta variant, physicians are still looking for effective ways to treat those who test positive for the

  • Dr. James Feinstein, a pediatrician who has dedicated his career to treating children with complex chronic conditions and severe neurological impairments, has developed a tool so parents may easily and comprehensively report their child’s symptoms. He has just published his research on this topic in JAMA Pediatrics and in JAMA Open.

  • The nation has been coping with the pandemic for more than a year, and in this time, researchers have learned a great deal about how to treat COVID-19. Yet they have also been faced with what they still must learn, including how to reach the individuals who have been most dramatically impacted by the disease and who could benefit the most from new treatments. A new $8.7 million grant from the

  • Virtual International Conference
    University Of Colorado Denver

    The Adult and Child Consortium for Health Outcomes Research and Delivery Science (ACCORDS), along with the Colorado Clinical and Translational Sciences Institute (CCTSI) at the University of Colorado Anschutz Medical Campus, is proud to welcome you to the second international Colorado Pragmatic Research in Health Conference (COPRH Con). Designed for junior faculty (K awards, career development

  • CCTS Bioethics Forum
    University Of Alabama At Birmingham

    The CCTS Bioethics Forum brings together researchers, bioethicists, students, community members, front-line research staff, and clinical staff to discuss ethical issues in research. This year's event will focus on the topic of "Equity and Trust for COVID-19 Testing, Treatment, and Vaccination: Where Do We Go from Here?"

  • University Of Colorado Denver

    The COVIDome Project at the University of Colorado Anschutz Medical Campus is a collaborative multidisciplinary project, led by Joaquin Espinosa, PhD, that aims to accelerate translational research in COVID19 by generating and integrating matched multi-omics and clinical datasets and making them broadly accessible through an online portal ahead of publication.

  • Pediatrician uses listening sessions to understand and address questions As the entire country eagerly awaits a safe and effective coronavirus vaccine, the issue of vaccine hesitancy is particularly relevant. Pediatrician Joshua Williams has been studying vaccine hesitancy in order to understand and address the questions religious Coloradans have.

  • FDA approves a drug that dramatically reduces seizure frequency Most physicians who conduct clinical trials say they were drawn to research because they wanted to discover new treatments and cures. Such findings are rare, but, every once in a while, clinical trials result in a new treatment that is life changing. This was the case with two trials led by pediatric neurologist Kelly Knupp, MD, who

  • CU Anschutz and CCTSI play a key role in developing antiviral medications and working to attenuate the inflammatory response. In just a few months, physicians have developed key findings through multiple clinical trials at CU Anschutz, testing previously FDA-approved drugs and new medications to battle COVID-19. “Two months ago I would not have guessed we’d have encouraging results so quickly,”

  • (UMHR) is designed to go above and beyond a typical participant recruitment platform because it allows for study use both ways: volunteers (both healthy and with specific medical conditions) and researchers can search for studies and find matches based on their interests and needs. This unique participant recruitment site has received national recognition and attention across the Clinical and Translational Science Award (CTSA) consortium. UMHealthResearch is now being deployed across the country at half a dozen other CTSA programs in Illinois and Florida, with more expressing interest as the word spreads about its unique design and interface.

  • More than 400 randomized clinical trials (RCTs) have been registered on, many are meant to answer similar questions but lack any method to combine data and evidence. By aggregating evidence across these trials, we can learn about interventions for COVID-19 as quickly and reliably as possible. The COVID-19 Collaboration Platform brings disparate research teams working on the same

  • Few would describe the pace of academic medical research as swift. Yet last month, the CCTSI disrupted its own processes and timelines by issuing a new rapid-release RFA to address COVID-19. The CCTSI COVID-19-Related Research Pilot Program – or C2R2 – supports the development of novel diagnostic and treatment methods and innovative technologies related to the COVID-19 outbreak.

  • When Betsy McFarland, MD began her infectious disease fellowship at Children’s Hospital Colorado in 1992, she treated children in the hospital who were living with HIV. The experience was pivotal. “You see a child that is suffering, and you think ‘what can we do better?’” says Dr. McFarland. “To be able to participate in research that will make that child’s life better or some other child’s life

  • CCTSI researchers play a vital role in new treatment expected to significantly improve quality of life and add years of life to those living with cystic fibrosis. Earlier this fall, the FDA approved a new breakthrough therapy for cystic fibrosis (CF), a genetic disease that leads to lung, digestive, endocrine and nutritional problems. Researchers from Children’s Hospital Colorado were part of a

  • Doctors and nurses—many of whom are also researchers—are working around the clock at UCHealth University of Colorado Hospital (UCH) to treat patients who are hospitalized with COVID-19. Over the next several months, research teams and caregivers will treat patients using four different drugs in the course of multiple clinical trials using Sarilumab, Remdesivir and Hydroxychloroquine. The Colorado

  • For some researchers who spend their days tucked away in a lab, the impact of their work may at times seem removed from the lives of real people. Not so for Dr. Kevin Messacar, pediatric infectious disease specialist. In his mind, he has considered himself a physician first, researcher second since he came to Children’s Hospital Colorado in 2009. Yet over the past several years, Messacar’s
  • Every day on the University of Colorado Anschutz Medical campus, hundreds of research studies and clinical trials take place. This summer, Professor Wendy Kohrt will be launching an exercise study called MoTrPAC (pronounced “motorpack”) and it stands for Molecular Transducers of Physical Activity Consortium. Funded by the National Institutes of Health (NIH), this six-year program is the largest

  • To say that early-career investigator Jesse Wilson, PhD, has recently found success is an understatement. Simply put, he is rocking it. In 2018, the biomedical optics engineer and assistant professor at Colorado State University won a Boettcher Foundation Webb-Waring Biomedical Research Award, and was named the Brownstein, Hyatt, Farber, & Schreck-MRA Young Investigator by the Melanoma Research

  • It is an interesting time to be a biomedical researcher in Colorado. In 2000, voters in the state made it legal to sell marijuana for medical use in adults; then in 2014, recreational marijuana was legalized for those over 21. For many years, some Colorado families who struggle to control their child’s epileptic seizures used cannabidiol, or CBD, as a medical treatment. (CBD is a naturally

  • Studying the effect of brief periods of activity vs. sustained exercise “My research aims to understand the mechanisms by which sedentary behaviors contribute to the development and progression of metabolic diseases, such as Type 2 Diabetes, obesity or metabolic syndrome,” says Dr. Audrey Bergouignan of the University of Colorado Anschutz Medical Campus. “With my research, I also hope to develop

  • The battle between good and evil is a theme usually reserved for blockbuster movies or literature. However, biomedical researcher Donald Leung, MD, is engaged in his own epic battle, pitting good bacteria against bad in order to treat atopic dermatitis or eczema—the world’s most common skin disease.

  • The Colorado Clinical and Translational Sciences Institute (CCTSI) is many things to many people — but in its essence — it supports biomedical researchers in their work. One key aspect of this mission is a web-based application for building and managing online research databases called Research Electronic Data Capture or REDCap. In April of this year, REDCap hosted its inaugural conference in

  • More 30 million Americans have Type 2 Diabetes related to the obesity epidemic—this is approximately 9.4 percent of the entire U.S. population. Physicians and researchers know that lifestyle interventions can prevent diabetes, slow its progression and decrease the need for medications. Importantly, improved physical fitness increases life expectancy. The problem is that having diabetes interferes

  • In 2012, the Colorado Clinical and Translational Sciences Institute (CCTSI) formally invited Colorado State University (CSU) to become an official Institute partner. The CCTSI is one of only a handful of the 58 NIH-funded CTSA Hubs across the nation that includes veterinary researchers—and translation to natural animal models—in its spectrum of translational research. Since 2012, the collaboration

  • Dr. Shikha Sundaram, with the help of the Colorado Clinical and Tranlational Science Insitutes’s pediatric Clinical and Translational Research Center, has been leading a clinical trial where children with non-alcoholic fatty liver disease (NAFLD) and sleep apnea use a CPAP machine at night. (CPAP stands for Continuous Positive Airway Pressure, and it is considered the standard of care for treating